X4 Pharmaceuticals, Inc. Common Stock XFOR
$3.50
-13.24%
at last close
Market Cap$347.51 million
P/E Ratio—
Div Yield—
Volume2.32M
52-Week Range
$1.35$4.83
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $10.00 (+185.3% upside)
Key Stats
- Today's Range
- $3.19 – $4.13
- 50-Day Range
- $3.19 – $4.82
- 52-Week Range
- $1.35 – $4.83
- Volume
- 2.32 million shs
- Average Volume
- 683K shs
- Market Cap
- $347.51 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.24
- Price / Sales
- —
Short Interest
- Short Interest
- 0.08%
- Days to Cover
- 2.97
About X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Related Stocks
Compare head-to-head: XFOR vs AMGN·XFOR vs MRNA·XFOR vs HALO·XFOR vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.